Ensemble is aggressively applying its proprietary drug discovery platform to develop novel small molecule therapies for cancer and other serious diseases. Their focus is on challenging disease targets that are not effectively treated by traditional drugs. With their lead program targeting the immune checkpoint IDO, Ensemble is working to provide new ways to treat cancer and other diseases. The company was founded in 2004 by Harvard Professor David R. Liu and has received support from a prominent group of investors.